5 reports

IN COMPARISON, AVAILABLE DATA ON LASMIDITAN## SHOWS ##% OF PATIENTS HAD PAIN RELIEF AT ##-HOURS, ##. ##% WERE PAIN FREE AND ##. ##% WERE MBS-FREE; FOR UBROGEPANT## PAIN RELIEF AT ##-HOURS WAS ##. ##%, WHILE ##. ##% OF PATIENTS WERE PAIN FREE; AND FOR RIMEGEP

  • Peripheral Vascular Device
  • Italy
  • Southern Europe
  • Market Size
  • Boston Scientific Corporation

NOW, WITH ONE PROCEDURE, PATIENTS REALIZE ALMOST IMMEDIATE PAIN RELIEF AND ARE ABLE TO QUICKLY GET BACK TO THEIR TREATMENT PLANS FOR OVERCOMING THEIR PRIMARY CANCER, " SAID DR.

  • Catheter
  • Clinical Trial
  • Peripheral Vascular Device
  • Robotics
  • Boston Scientific Corporation

In patients with no prior IACS, pain relief in the ZILRETTA group was significantly improved compared with PBO through ## weeks after treatment (p=##. ##).

  • Healthcare
  • Peripheral Vascular Device
  • North America
  • United States
  • Market Size

CR## in acute postoperative pain in patients undergoing a range of abdominal surgeries.

  • Peripheral Vascular Device
  • Canada
  • North America
  • Forecast
  • Market Size

THE COMPANY SAID SCS THERAPY CAN PROVIDE PROVEN, MEANINGFUL CHRONIC PAIN RELIEF FOR MANY PATIENTS, WHILE IMPROVING QUALITY OF LIFE AND REDUCING OR EVEN ELIMINATING A PATIENT' S USE OF PAIN MEDICATION.

  • Clinical Trial
  • Health Services
  • Peripheral Vascular Device
  • Therapy
  • GlobalData's company